NCT06391164View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of XC243 in Patients With Exacerbation of Chronic Cystitis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Cystitis
Interventions
DRUG

XC243 25 mg

Patients will receive the Investigated Product (IP) once in the morning at least 30 minutes before eating for 7-10 days

DRUG

XC243 50 mg

Patients will receive the IP once in the morning at least 30 minutes before eating for 7-10 days

DRUG

XC243 75 mg

Patients will receive the IP once in the morning at least 30 minutes before eating for 7-10 days

DRUG

Placebo

Patients will receive the IP once in the morning at least 30 minutes before eating for 7-10 days

Trial Locations (8)

119571

Unimed-S Cjsc, Moscow

191119

"LLC Research Center Eco-Safety", Saint Petersburg

195427

"St. Petersburg State Budgetary Healthcare Institution City Polyclinic № 112", Saint Petersburg

196143

"LLC Research Center Eco-Safety", Saint Petersburg

196158

"LLC Clinic Zvezdnaya", Saint Petersburg

North-West Center of Evidence-Based Medicine Jsc, Saint Petersburg

197374

Prime Rose Medical Center LLC, Saint Petersburg

199178

"St. Petersburg State Budgetary Healthcare Institution City Polyclinic No. 4", Saint Petersburg

All Listed Sponsors
lead

PHARMENTERPRISES LLC

INDUSTRY